دورية أكاديمية
Effect of IBD medications on COVID-19 outcomes: results from an international registry
| العنوان: | Effect of IBD medications on COVID-19 outcomes: results from an international registry |
|---|---|
| المؤلفون: | Ungaro, R.C., Brenner, E.J., Gearry, R.B., Kaplan, G.G., Kissous-Hunt, M., Lewis, J.D., Ng, S.C., Rahier, J.-F., Reinisch, W., Steinwurz, F., Underwood, F.E., Zhang, X., Colombel, J.-F., Kappelman, M.D. |
| المصدر: | Gut |
| سنة النشر: | 2020 |
| المجموعة: | Carolina Digital Repository (UNC - University of North Carolina) |
| الوصف: | Objective We sought to evaluate COVID-19 clinical course in patients with IBD treated with different medication classes and combinations. Design Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We used multivariable regression with a generalised estimating equation accounting for country as a random effect to analyse the association of different medication classes with severe COVID-19, defined as intensive care unit admission, ventilator use and/or death. Results 1439 cases from 47 countries were included (mean age 44.1 years, 51.4% men) of whom 112 patients (7.8%) had severe COVID-19. Compared with tumour necrosis factor (TNF) antagonist monotherapy, thiopurine monotherapy (adjusted OR (aOR) 4.08, 95% CI 1.73 to 9.61) and combination therapy with TNF antagonist and thiopurine (aOR 4.01, 95% CI 1.65 to 9.78) were associated with an increased risk of severe COVID-19. Any mesalamine/sulfasalazine compared with no mesalamine/sulfasalazine use was associated with an increased risk (aOR 1.70, 95% CI 1.26 to 2.29). This risk estimate increased when using TNF antagonist monotherapy as a reference group (aOR 3.52, 95% CI 1.93 to 6.45). Interleukin-12/23 and integrin antagonists were not associated with significantly different risk than TNF antagonist monotherapy (aOR 0.98, 95% CI 0.12 to 8.06 and aOR 2.42, 95% CI 0.59 to 9.96, respectively). Conclusion Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19. No significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.MKH should be changed to MDK for co-last author line |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | https://doi.org/10.17615/6t00-gd31Test; https://cdr.lib.unc.edu/downloads/h415pk14w?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/h415pk14wTest |
| DOI: | 10.17615/6t00-gd31 |
| الإتاحة: | https://doi.org/10.17615/6t00-gd31Test https://cdr.lib.unc.edu/downloads/h415pk14w?file=thumbnailTest https://cdr.lib.unc.edu/downloads/h415pk14wTest |
| حقوق: | http://rightsstatements.org/vocab/InC/1.0Test/ |
| رقم الانضمام: | edsbas.C1047436 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17615/6t00-gd31 |
|---|